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Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel 
condition characterised by a relapsing and remitting 
course. Symptom control has been the traditional 
mainstay of medical treatment. It is well known that 
histological inflammatory activity persists despite 
adequate symptom control and absence of endoscopic 
inflammation. Current evidence suggests that presence of 
histological inflammation poses a greater risk of disease 
relapse and subsequent colorectal cancer risk. New 
endoscopic technologies hold promise for developing 
endoscopic markers of mucosal inflammation. Achieving 
endoscopic and histological remission appears be the 
future aim of medical treatments for UC. This review 
article aims to evaluate the use of endoscopy as a tool 
in assessment of mucosal inflammation UC and its 
correlation with disease outcomes.
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Core tip: Endoscopy is the mainstay of assessing 
disease activity in ulcerative colitis. Mucosal healing 
(MH) is an accepted end point in clinical trials. Recent 
data suggest that complete MH is associated with lower 
relapse rates and better long term outcomes. Advanced 
imaging techniques like high definition endoscopy, 
narrow band imaging, magnification endoscopy, 
chromoendoscopy and endomicroscopy help in detailed 
assessment of mucosa and the submucosal vasculature. 
In this review article we aim to look at the correlation 
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between these endoscopic assessment modalities and 
clinical outcomes.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel 
condition characterised by mucosal inflammation of 
the rectum and colon. It is associated with a relapsing 
and remitting disease course. The exact aetiology of 
the disease remains elusive although genetic linkage, 
auto immune causes and environmental influences 
have been postulated. Approximately 25% of patients 
with UC experience acute exacerbation of their disease 
activity during the course of their disease[1]. Colectomy 
rate increases with more than one hospital admissions 
with acute severe UC, reaching up to 40% after two 
admission[1]. Truelove and Witts criteria established 
over 60 years ago, estimates the severity of the disease 
and predicts the need for colectomy using clinical 
and biochemical scores[2]. Current treatment goals in 
UC focus on keeping the disease in remission and a 
colectomy free survival.
There have been significant scientific advances 
in both diagnosis and management of UC in the last 
two decades. The use of Immunomodulators like Aza­
thioprine, Cyclosporine, and biologic agents like Anti­
Tumour necrosis factors alpha has changed the way 
patients with UC are managed in modern day practice. 
Advances in medical management of UC have seen a 
fall in colectomy rates[3].
A flare up in disease activity in UC is difficult to 
predict but a reliable biomarker would be important in 
guiding appropriate therapy. Commercially available 
serum and faecal biomarkers have been ineffective 
in positively predicting disease relapse in UC. Sero­
logical markers available for clinical and research 
use includes C­reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), white blood cells, Platelets, 
1­acid glycoprotein, serum amyloid A­protein, 2­globulin, 
lactoferrin, orosomucoid and thrombopoietin. Faecal 
biomarkers are thought to be non­invasive and are 
relatively inexpensive. Available faecal biomarkers 
include a1­antitrypsin excretion, lysozyme excretion, 
calprotectin, lactoferrin, Myeloperoxidase. Faecal 
calprotectin has generated the most interest among 
researchers and clinicians. However, in a meta­analysis 
consisting of 6 prospective studies looking at the use 
of faecal calprotectin in predicting clinical flares in 
inflammatory bowel disease (IBD), Mao et al[4] report 
a pooled sensitivity of only 78% and specificity of 
73%. Endoscopy is the main tool used by physicians 
in assessing severity and extent of the disease in UC 
in clinical practice. It is a reliable tool in assessment 
of disease activity during flare up of symptoms. But in 
inactive disease persistent microscopic inflammation 
is often seen despite the normal appearance of colonic 
mucosa on standard white light endoscopy (WLE)[5]. 
Histologically active disease is associated with greater 
risk of subsequent relapse[6­8]. Studies using standard 
WLE fail to predict relapse in quiescent UC[5,7,8], whereas 
studies using advanced endoscopic imaging modalities 
seem to hold promise[9­11].
In this review article we aim to discuss the use of 
endoscopic modalities in assessment of disease activity 
in UC, its correlation with clinical outcomes, and 
endoscopic predictors of relapse.
ENDOSCOPY IN UC
Endoscopy is essential in diagnosing UC, obtain biopsies 
and distinguishing from Crohn’s disease. Direct mucosal 
visualisation allows physicians to assess extent and 
severity of the disease during flare ups and observe 
effectiveness of treatment during follow up. In addition 
to this it is the only available test to identify and resect 
dysplastic lesions during surveillance for colorectal 
cancer in patients with long standing colitis.
Endoscopic assessment of the mucosa for pa­
thological diagnosis is largely operator dependant. 
Although agreement among beginners was good at 
the extremes of the disease, concordance for certain 
endoscopic features like granularity, erosions and 
friability was still poor and identified the need for 
training to improve endoscopic diagnosis[12,13]. Training 
has shown to improve diagnostic yield in endoscopy 
in trainee endoscopists. Studies suggest that among 
experienced endoscopists there is a good inter­observer 
agreement in UC related endoscopic findings[13].
There are at least ten scoring systems designed to 
assess the disease activity in UC since the development 
of first such score by Baron et al[14] in 1964. Table 1 
provides details of scores using endoscopic activity 
alone and Table 2 details of scores with mainly clinical 
and biochemical parameters with or without endoscopic 
features. Many of these scoring systems use clinical, 
biochemical and endoscopic components in an attempt 
to grade the disease activity[15]. Endoscopic parame­
ters of assessment include mucosal vascular pattern 
(MVP), friability and mucosal damage. Mayo endoscopic 
sub score is an endoscopic component of full Mayo 
score[16]. Both Baron score and Mayo endoscopic sub 
score have been used in clinical trials; however these 
scores have not been validated rigorously[15]. Recently 
Travis et al[13,17] have designed and validated a new 
scoring system using endoscopic “descriptors” called 
ulcerative colitis endoscopic index of severity (UCEIS). 
Ten IBD experts evaluated sigmoidoscopic videos of 
varying degree of endoscopic inflammation seen in UC. 
Inter and intra­investigator reliability was tested using 
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Table 2  Disease activity indices with endoscopic and non-endoscopic components
Disease activity index Endoscopic variables Non-endoscopic variable
Powell-Tuck score[20] Bleeding Wellbeing, Abdominal pain, stool frequency and consistency, 
Bleeding, Anorexia, nausea and vomiting, EIM, Temperature 1982
Sutherland index[21] Friability, Bleeding Stool frequency, Bleeding, Physician’s rating of disease activity
1987
Mayo score[16] Erythema, MVP, Friability, erosions, ulcers, 
spontaneous bleeding
Stool frequency, Bleeding, Physician’s global assessment
1987
Improvement based on 
individual symptom scores[22]
Mucosal oedema, MVP, Granularity, Friability, 
Petechiae, Ulceration, Spontaneous bleeding
Rectal bleeding, Stool frequency, Abdominal pain, PFA, PGA
2002
EIM: Extra-Intestinal Manifestations; MVP: Mucosal vascular pattern; PGA: Physician global assessment; PFA: Patient functional assessment.
Kappa statistics. In the validation phase they report a 
satisfactory intra and inter­investigator reliability using 
this score. No significant difference was observed 
when investigators were tested with or without the 
knowledge of clinical details of the subjects.
ENDOSCOPY IN ACUTE SEVERE COLITIS
Endoscopy plays a vital role is disease assessment in 
acute flares of UC. Limited examination of the colon 
by flexible sigmoidoscopy is enough to establish 
the diagnosis and obtain biopsies. Radiological 
examinations like abdominal X­rays and sometimes 
computed tomography (CT) scans are carried out prior 
to endoscopic examinations. Minimal air insufflation 
is used during endoscopic procedure to avoid misin­
terpretation of subsequent X­ray images as toxic 
megacolon.
Sigmoidoscopy is commonly performed during UC 
flare ups and it is thought to be sufficient for assessing 
disease severity. Colonoscopy is avoided until the 
disease is settled, mainly due to fear of complications 
such as perforation during severe flare. However there 
are few prospective studies to validate this widely used 
practice. In the only published study to date, Carbonnel 
et al[23] demonstrated that colonoscopic examination 
is safe in acute flare up of UC, and helps in identifying 
patients at high risk of colectomy. In their cohort of 85 
consecutive patients with acute sever colitis, extensive 
deep ulcerations were found in 46 patients. Forty­
three/forty­six patients with deep ulceration underwent 
colectomy and histology in 42/43 patients showed 
deep ulcerations extending up to muscular layer. Thirty 
of thirty­nine patients with moderate colitis responded 
to medical therapy. They did not report any major 
complications apart from one dilated colon in their 
cohort. The authors conclude that a full colonoscopy 
was safe in acute severe flare of colitis and also helped 
in predicting course of the disease and short term 
outcome. It is important to know that all endoscopic 
procedures in this study group were performed by 
an experienced colonoscopist; hence care must be 
taken in generalising these findings to all endoscopists. 
Secondly this study was conducted in the pre­biological 
treatment era which could account for the high rates of 
colectomy.
ENDOSCOPY IN DISEASE REMISSION
The aims of endoscopy performed during clinical 
disease remission are to assess if there is reduction of 
endoscopic activity after a flare, ascertain if mucosal 
healing (MH) is achieved, to obtain biopsies and screen 
for dysplastic lesions.
MH is increasingly recognised as a therapeutic 
endpoint in clinical trials. Although there is no consensus 
definition of MH, the International organisation of 
IBD proposed the following criteria to define MH: 
absence of friability, blood, erosions and ulcers in 
all visualised segments of the colonic mucosa[15]. 
Essentially disappearance of endoscopic lesions 
such as erosions and ulcers is called as MH. Drugs 
such as 5­aminosalicylates, immunomodulators like 
azathioprine, methotrexate and biological agents 
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Table 1  Disease activity indices with endoscopic component alone
Disease activity index Endoscopic variables 
Baron score[14] Bleeding and MVP
1964
Rachmilewitz endoscopic index[18] Granulation, MVP, Mucosal vulnerability, Mucosal damage
1989
UC colonoscopic index of severity (UCCIS)[19] MVP, Granularity, Ulceration, Bleeding, Segmental assessment of endoscopic severity, Global 
assessment of endoscopic severity2013
UC endoscopic index of severity (UCEIS)[13] MVP, Bleeding, Erosions and Ulcers
2013
MVP: Mucosal vascular pattern; UC: Ulcerative colitis.
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DOES STANDARD WLE CORRELATE 
WITH HISTOLOGICAL ACTIVITY?
The presence of deep ulcerations, extensive disease, 
higher median inflammation seen on WLE corresponds 
to more severe disease and are associated with higher 
colectomy rates[23,38]. MH is associated with better 
outcomes such as decreased relapse rates and the need 
for surgical interventions[6,30,31,33,39]. Use of conventional 
colonoscopy is restricted to assessment of disease 
activity and extent of the disease during disease flare; 
however colonoscopic findings in remission does not 
correlate well with the histological activity nor are 
they predictive of relapses. Table 4 provides details of 
studies comparing white light endoscopic activity and 
histological activity and their potential in predicting 
disease outcomes in UC.
Histological inflammation has been shown to persist 
despite normal endoscopic findings in both prospective 
and retrospective studies[5­8,40,41]. Histological markers 
of inflammation such as basal plasmacytosis, basal 
lymphocytosis and chronic inflammatory infiltrates 
were found in biopsies from endoscopically normal 
looking mucosa. These histological markers were 
associated with increased risk of subsequent relapse. 
The rate of relapse was reported to be between 
20%­57.7% among UC patients with quiescent disease 
(Table 4).
DOES ENDOSCOPY PREDICT DISEASE 
RELAPSE?
In a recent prospective study involving 41 patients 
with UC who had undergone colonoscopy before and 
after receiving Tacrolimus, Ikeya et al[43] studied the 
outcomes of patients assessed by two of the disease 
activity score; the Mayo endoscopic subscore and the 
UCEIS. They reported better correlation of endoscopic 
assessment of disease activity using UCEIS and also in 
predicting relapse free survival. In another prospective 
(infliximab, adalimumab, golimumab, vedolizumab, 
etc.) are used in the induction of remission and 
maintenance of MH in UC[24­30]. MH is associated with 
favourable short and long term clinical outcomes 
like reduced hospitalisation due to flares of disease, 
decreased colectomy rates and lower incidence of 
subsequent colorectal cancers[6,31­34].
DOES ENDOSCOPY CORRELATE WITH 
CLINICAL SYMPTOMS?
Generally it is considered that clinical symptoms, 
biochemical markers of inflammation, endoscopic 
findings and histological grading help in assessing the 
severity of the disease in UC. It is not uncommon to 
find that clinical symptoms and endoscopic findings do 
not correlate. Table 3 contains the studies comparing 
endoscopic activity with clinical symptoms. Karoui 
et al[35] compared the endoscopic findings of patients 
in remission whereas Osada et al[36] examined patients 
with varying grades of severity. In both the studies 
serological markers (CRP and ESR) correlated well 
with the disease activity. However conflicting results 
were noted when comparing clinical symptoms with 
endoscopic findings (Table 3). Osada et al[36] reported 
that clinical symptoms correlated well with the disease 
of left colon whereas CRP and ESR reflected well with 
right sided disease. No significant association was 
noted by Karoui et al[35]. Different clinical activity indices 
used in the above two studies (Rachmilewitz score and 
Lichtiger index respectively) may have contributed to 
the differences. However, in a prospective study Turner 
et al[37] compared different clinical activity indices and 
their respective abilities to assess disease activity. They 
noted that the Rachmilewitz score and Lichtiger index 
had comparable “discriminative average” which is the 
ability to differentiate patients in clinical remission with 
those patients with active disease [Rachmilewitz score­ 
0.92 (95%CI: 0.87­0.98) and Lichtiger index­ 0.90 
(95%CI: 0.84­0.97)]. 
Table 3  Correlation of endoscopic activity with clinical symptoms
Ref. Study characteristics Results
Karoui et al[35] Prospective observational study. CRP correlated well with DAI and Rachmilewitz score
2011 101 patients with UC in remission. Correlation between DAI and Rachmilewitz was not statistically 
significant 
Tunisia CRP, Disease activity index and Rachmilewitz scores used
Osada et al[36] Prospective observational study. Clinical symptoms correlated with left sided disease activity.
2008 54 patients with UC. CRP and ESR correlated well with right sided inflammation.
Japan CRP, ESR, Mayo endoscopic subscore, Lichtiger’s clinical activity 
scores used.
Turner et al[37] Prospective observational study. Disease activity was best assessed by Walmsley and PUCAI 
followed by Partial Mayo score and Rachmilewitz2009 86 patients with UC. Disease activity was measured using 9 
different activity indices
Canada
CRP: C-reactive protein; DAI: Disease activity index; ESR: Erythrocyte sedimentation rate; PUCAI: Paediatric ulcerative colitis activity index; UC: Ulcerative 
colitis.
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study of 82 patients with UC, a score of 0­1 on UCEIS 
after treatment with Infliximab had favourable long 
term outcomes[44].
Does advanced imaging modalities predict relapse
Advanced imaging modalities such as magnification 
colonoscopy (MC), narrow band imaging (NBI), 
iScan, Fujinon intelligent colour enhancement (FICE), 
autofluorescence imaging (AFI), chromoendoscopy, 
confocal laser endomicroscopy (CLE) and endocytology, 
etc. enable real time mucosal assessment in greater 
detail. Imaging modalities such as NBI, MC and 
magnification chromoendoscopy have been evaluated, 
mainly by Japanese investigators, for their ability to 
predict relapse in UC (Table 5). Figure 1A­D shows the 
appearances of inflamed colonic mucosa in patients 
with colitis using standard definition, high definition, 
NBI and chromoendoscopy respectively. Image 
enhanced endoscopic techniques appear to improve 
the visualization of inflammation in colonic mucosa but 
large scale clinical studies are needed to ascertain the 
relevance of these findings to clinical outcomes.
MC: Optical enhancement of image from six to 150 
fold occurs due to a moving camera at the tip of the 
endoscope[45]. In MC the image undergoes optical 
enhancement and hence the pixels are not distorted 
and the image quality is not compromised. Hence 
the image appears sharp and allows assessment of 
surface pattern in detail. Regular pit pattern seen 
under MC is associated with a significantly reduced 
risk of relapse[9,10]. Patients with distorted MVP, abnor­
malities in epithelium or pit pattern have a higher 
grade of inflammation on histology and relapse sub­
sequently[9­11,46,47]. In one recent study MC with NBI­
lead target biopsies seems to predict long term 
outcomes[48].
Chromoendoscopy and NBI: Chromoendoscopy 
is examination of the colonic mucosa after spraying 
dye which contrast enhances and highlights mucosal 
abnormalities allowing precision biopsies. NBI, also 
called as “virtual chromoendoscopy” or “dye­less 
chromoendoscopy”, utilises optical filters and uses 
shorter wavelengths of light (between 415­540 nm) 
which intensely absorbed by haemoglobin. This 
allows examination of the vasculature and surface 
pattern in detail. Use of NBI in predicting relapse is 
controversial. Kudo et al[46] in their prospective study 
evaluated the MVP observed under WLE and NBI. 
NBI findings of obscure MVP correlated well with the 
histological markers of inflammation. Although this 
study did not report any outcome data on relapse, 
we know that the histological inflammation leads to 
subsequent relapse. More recently a prospective study 
from Spain of 67 patients with UC in sustained clinical 
Table 4  Correlation between white light endoscopy and histology in ulcerative colitis
Ref. Study characteristics and aims Results
Bitton et al[8] Prospective observational study 36.4% patients relapsed
2001 74 patients in clinical and endoscopic remission were 
included
Younger age, multiple previous relapses (women), and basal 
plasmacytosis on histology predicted relapse.
United States Followed up for a year or until the patients relapsed. CRP, ESR, IL-1b, -6, 15, ANCA was non-predictive of relapse.
Azad et al[41] Prospective observational study 57.7% patients relapsed
2011 26 patients with clinical and endoscopic remission were 
included
Increased Eosinophils and Neutrophils were predictors of relapse.
India Monthly follow up for a year or until the patients relapsed. Hb, CRP, ESR, IL-6 were not predictive of relapse.
Bessissow et al[7] Retrospective study Microscopic inflammation was found in 40% of patients.
2012 75 patients with endoscopically inactive disease (Mayo score 
0)
Basal plasmacytosis and histological activity (Geboes score ≥ 3.1) 
predicted relapse.
Belgium Time to relapse was noted
Lemmens et al[40] Retrospective study Significant correlation with Mayo endoscopic subscore and histology 
noted in extremes of disease (inactive and acute severe disease)2013 131 patients with known UC
Belgium Correlation of endoscopy and histology
Rosenberg et al[5] Prospective observational study 54% of patients with quiescent disease had signs of histological 
inflammation.2013 103 UC patients in clinical remission
United States Correlation of endoscopy and histology
Feagins et al[6] Retrospective study of 51 patients. 20% of patients had flare up within 12 mo.
2013 colonoscopy for surveillance Basal lymphocytosis, disruption of crypt architecture, erosions and 
ulcers predicted relapse.
United States Correlation of endoscopic and histological activity
Zenlea et al[42] Prospective study 23% of patients relapsed
2016 179 patients included Histological activity with Geboes score ≥ 3.1 was strongest predictor of 
relapse.
United States Baseline Mayo endoscopic score and Geboes score for 
histology noted
Follow up period was 12 mo
UC: Ulcerative colitis; Hb: Haemoglobin; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; IL-6: Interleukin-6; ANCA: Anti-nutrophil 
cytoplasmic antibody.
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remission investigated chromoendoscopy, NBI and 
faecal calprotectin in predicting clinical flares. In this 
study advanced endoscopy suing NBI failed to predict 
relapse within one year[49].
CLE: CLE allows visualisation of cellular structures and 
assessment of their function in real time. Contrast 
agent such as fluorescein is administered systemically 
and laser light is emitted via CLE. The reflected 
endoscopic image is reprocessed for microscopic 
examination in such a way that the resultant image is 
enhanced to a 1000 fold magnification. CLE detects 
barrier dysfunction in the epithelium in patients with 
IBD[50]. Mucosal inflammation in IBD results in barrier 
dysfunction which is seen as increased fluorescence 
leak and widening of crypt diameter along with 
intercept distance on CLE. A composite score developed 
by Buda et al[51] using fluorescence leak, and crypt 
diameter have shown predictive capabilities for 
disease outcomes in quiescent UC patients during 12 
mo follow up[50­52]. A recent study from Karstensen 
et al[53] reported parameters for distinguishing active 
and inactive UC with CLE. In this prospective study 
the authors examined colonic mucosa from twenty 
two patients with clinical symptoms of relapse and 7 
patients with inactive disease referred for surveillance 
purposes served as controls. This study demonstrated 
that fluorescein leak, microerosions, tortuosity of 
crypts, distortion of crypt opening, decreased crypt 
density and presence of inflammatory infiltrates 
were significantly higher in active compared to 
inactive colitis. They also noticed improvement in the 
crypt architecture was associated with histological 
improvement following treatment of active colitis.
Endocytoscopy: Data on use of endocytoscopy (EC) 
in prediction of relapse in UC is limited. Maeda et al[54], 
in a retrospective study of patients who underwent 
endocytoscopic­NBI (EC­NBI) compared the images 
with histological inflammation. EC­NBI was found 
to be highly useful in assessing histological activity 
with a sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy of EC­NBI for 
diagnosis of acute inflammation to be 84%, 100%, 
87.1%, 100% and 92.3%. There was not data on 
relapse rate provided in this study.
Endoscopic assessment with AFI and iScan have 
been found to correlate well with histological activity, 
they have not been used to assess relapse prediction 
in UC[55,56]. The FICE was however found not helpful in 
improving and further characterisation of endoscopic 
findings in IBD[57].
Spectroscopy: More recently we studied the use of 
Raman spectroscopy to identify MH and inflammation 
in UC. We observed that three carotenoid peaks 
were twice as intense in the inflamed mucosa and 
two phospholipid peaks were significantly lower in 
the normal mucosa. These five peaks seen on the 
spectroscopy could be used reliably to distinguish 
Table 5  Relapse prediction using advanced imaging techniques
Ref. Imaging modality Study characteristics Results
Watanabe et al[9] Magnification colonoscopy 
with chromoendoscopy
Prospective study 70% of patients with mucosal defects 
identified by MC had a flare up within 12 
mo
2009 57 patients with clinical and endoscopic remission were 
enrolled for MC examination and followed up for 12 mo
Japan
Nishio et al[10] Magnification colonoscopy 
with chromoendoscopy
Prospective study 29% of patients relapsed. Significant 
correlation seen between pit pattern 
abnormalities and relapse rate. 
2006 113 patients with UC in remission were enrolled. Pit 
pattern in rectal mucosa assessed using MC. Followed up 
for 12 mo
Japan
Fujiya et al[11] Magnification colonoscopy 18 patients with UC in remission underwent MC and 
follow up
7 out of 9 (77.7%) with minute epithelial 
defect had a flare.2002
Japan 
Kudo et al[46] NBI Prospective study Obscured MVP had good correlation with 
the histological activity. 2009 157 colonic segments among 30 patients were examined 
under WLE and NBI
Japan
Jauregui-Amezaga 
et al[49]
Chromoendoscopy and NBI Prospective study 27% relapsed during follow up
2014 64 patients with clinical and endoscopic remission for at 
least 3 mo were included. 1 year follow up.
Neither NBI nor chromoendoscopy 
predicted relapse
Spain
Osada et al[55] AFI Retrospective study The green component of AFI correlated 
closely with the inflammatory activity2011 572 images from 42 patients were correlated with 
histological activity
Japan
MC: Magnification colonoscopy; MVP: Mucosal vascular pattern; AFI: Autofluorescence imaging; NBI: Narrow band imaging.
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active from quiescent UC[58].
CONCLUSION
Endoscopy is a useful tool in the clinical management 
of UC. Although standard WLE is the commonly used 
in day to day practice, it has its limitations in assessing 
disease activity and predicting disease course. 
Advanced imaging modalities show promising results 
but they are expensive, involve a steep learning curve 
and are time consuming. Endoscopic modalities such 
as CLE and EC are still restricted to research use and 
cannot be advocated for routine assessment of IBD. 
Advanced endoscopy improves visualisation of mucosal 
surface structure and vascularity and hold promise 
for predicting disease outcomes. Development of 
endoscopic markers using these advanced technologies 
in well­designed prospective clinical studies is essential 
to develop robust markers for predicting disease 
course in patients with UC.
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